CRISPR Therapeutics AG
CRISPR Therapeutics AG is a gene-editing biopharmaceutical company built around CRISPR/Cas9 technology and the development of gene-based medicines for serious diseases. Its most important commercial milestone is CASGEVY, the first approved CRISPR-based therapy, which it co-develops and co-commercializes with Vertex Pharmaceuticals for sickle cell disease and transfusion-dependent beta thalassemia. Beyond hemoglobinopathies, the company is building a pipeline across in vivo editing, CAR T approaches, regenerative medicine, and type 1 diabetes. The business is still heavily research- and development-driven, with value creation tied to clinical progress, regulatory approvals, manufacturing execution, and partner-led commercialization.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved CRISPR-based medicine and related commercialization activities for hemoglobinopathies.
Programs that deliver CRISPR-based therapeutics directly into the body for liver and other targets.
Engineered cell therapy candidates developed using CRISPR editing and partner collaborations.
CRISPR-X and other next-generation editing technologies designed to expand the platform.
Milestones, option fees, and shared development economics from strategic alliances such as Vertex.
Products
Reported · share of revenue- Collaboration Revenue93.8 %
- Grant6.2 %
Source: 10-K FY2024, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
The company’s direct commercial customers are patients with severe genetic diseases, but the purchasing and reimbursement process runs through specialty healthcare systems, hospitals, transplant centers, and payers. For CASGEVY, treatment is concentrated in qualified centers that can perform the complex cell collection, conditioning, and infusion workflow required for ex vivo gene editing. In practice, Vertex and CRISPR Therapeutics rely on physicians, treatment centers, and reimbursement authorities to drive adoption, while the company’s pipeline programs are still bought indirectly through clinical trial participation and partner funding. The customer base is therefore a mix of healthcare providers, payers, and strategic partners rather than a broad end-market consumer base.
Patients with severe sickle cell disease or transfusion-dependent beta thalassemia who are eligible for CASGEVY through specialized treatment centers.
Centers that perform patient identification, cell collection, conditioning, infusion, and follow-up for approved and clinical-stage cell therapies.
Insurers and government health systems that approve and reimburse expensive one-time gene therapies based on clinical and economic evidence.
Partners such as Vertex that co-develop, co-commercialize, manufacture, or fund programs to accelerate development and market access.
Patients enrolled in early- and mid-stage studies for in vivo, CAR T, regenerative medicine, and diabetes programs.
Strategy
The company’s strategy is to convert CRISPR/Cas9 from a platform into a portfolio of approved and clinically differentiated medicines across multiple disease areas. Near term, the priority is to expand the commercial and clinical footprint of CASGEVY while supporting Vertex-led commercialization and manufacturing execution. Medium term, management is pushing in vivo editing, CRISPR-X next-generation modalities, and delivery technologies such as non-viral systems and LNPs to broaden the addressable patient population beyond ex vivo cell therapy. The company is also using partnerships to share development risk, access disease-area expertise, and accelerate programs in hemoglobinopathies, DMD, DM1, diabetes, and other therapeutic areas.
The approved product is the clearest path to near-term value creation and validates the platform.
In vivo delivery could open larger markets than ex vivo cell therapy and reduce treatment complexity.
New editing chemistries and delivery methods are needed to stay competitive as the field evolves.
Collaborations reduce capital intensity and provide access to disease expertise and commercialization capabilities.
Geography
The company is headquartered in the United States but operates as a global gene-therapy developer with clinical, regulatory, and commercial exposure across the U.S., Europe, and other major markets. CASGEVY has been approved in the United States and other countries, so commercialization depends on country-by-country reimbursement and treatment-center readiness. The reports also highlight increasing genetic-medicine competition in China, which makes Asia an important strategic and competitive reference point even if the company’s own revenue disclosure is not broken out by country. Because manufacturing and treatment delivery for cell therapies are complex, geography matters not only for market access but also for regulatory approvals, supply chain coordination, and partner execution.
Risks
The company faces substantial clinical, regulatory, and manufacturing risk because its business depends on proving that highly complex gene-editing therapies are safe, effective, and scalable. CASGEVY’s commercialization is also exposed to partner dependence, since Vertex has significant control over the program and is the manufacturer and exclusive license holder. Competition is intense and technologically fluid, with rival approaches including base editing, RNA editing, TALENs, and traditional gene therapy potentially displacing CRISPR/Cas9 in some indications. Broader industry risks include changing FDA, EMA, and MHRA expectations, supply-chain or lot-failure issues, and the possibility that reimbursement or market access for high-cost therapies develops more slowly than expected.
- Clinical development failure or delayImpact: HighLikelihood: Medium
The pipeline depends on successful preclinical and clinical outcomes, and setbacks can stop or postpone commercialization.
Exposure: All pipeline programs
- Manufacturing quality and supply-chain disruptionImpact: HighLikelihood: Medium
Cell and gene therapies require tightly controlled manufacturing; deviations can cause lot failures, recalls, and trial delays.
Exposure: CASGEVY and future cell therapies
- Partner dependence on VertexImpact: HighLikelihood: Medium
Vertex is the manufacturer and exclusive license holder of CASGEVY and has significant control over the program.
Exposure: CASGEVY commercialization
- Regulatory tightening for gene therapyImpact: MediumLikelihood: Medium
FDA, EMA, and MHRA scrutiny can delay or prevent approvals and increase development burden.
Exposure: Global development and commercialization
- Competitive displacement by alternative editing technologiesImpact: MediumLikelihood: Low
Base editing, RNA editing, TALENs, and other platforms may prove more attractive in certain indications.
Exposure: Platform and pipeline
Accounting
Judgemental itemsRevenue depends on contract terms, performance obligations, and milestone timing rather than steady product sales.
Impact: Can cause significant quarterly volatility in reported revenue
Clinical and preclinical programs require estimates for outsourced research, trial costs, and vendor obligations.
Impact: Affects operating expenses and loss volatility
Shared development and commercialization arrangements require careful allocation and presentation of proceeds and costs.
Impact: Can materially affect revenue mix and margin interpretation
Investment balances can move with market conditions and maturity profile.
Impact: Affects other income and liquidity presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Vertex Pharmaceuticals Incorporated
VRTX · Pharmaceutical Preparations
Vertex Pharmaceuticals is a U.S.-based biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases.
Caribou Biosciences, Inc.
CRBU · Biological Products, (No Diagnostic Substances)
Metagenomi Therapeutics, Inc.
MGX · Biological Products, (No Diagnostic Substances)
Vera Therapeutics, Inc.
VERA · Pharmaceutical Preparations
Beam Therapeutics Inc.
BEAM · Biological Products, (No Diagnostic Substances)
Crescent Biopharma, Inc
CBIO · Pharmaceutical Preparations
Last updated: 24/09/2026